Editor: Michelle Prudhomme

Advances in Anticancer Agents in Medicinal Chemistry

Volume 1

eBook: US $119 Special Offer (PDF + Printed Copy): US $214
Printed Copy: US $155
Library License: US $476
ISSN: 2589-2819 (Print)
ISSN: 2214-4331 (Online)
ISBN: 978-1-60805-712-2 (Print)
ISBN: 978-1-60805-493-0 (Online)
Year of Publication: 2013
DOI: 10.2174/97816080549301130101


Advances in Anticancer Agents in Medicinal Chemistry is an exciting eBook series comprising a selection of updated articles previously published in the peer-reviewed journal Anti-Cancer Agents in Medicinal Chemistry. The first volume gathers reviews of many classes of drugs of contemporary interest for cancer therapy and is devoted to small molecules inhibitors of various proteins involved in cancer development such as Casein kinase 2 (CK2), Protein kinase B (PKB), mTOR, Hsp90, P-glycoprotein (P-gp), Kinesin spindle protein (KSP), Cyclooxygenase 2 (COX-2), Histone deacetylase enzymes (HDACs) and Topoisomerase I.

Advances in Anticancer Agents in Medicinal Chemistry will be of particular interest to readers interested in anti cancer drug therapy as the series provides additional value to scientific research by entailing an approach of bringing relevant reviews up-to-date and thus more valuable for reference purposes.

Indexed in: Book Citation Index, Science Edition, Ulrich's Periodicals Directory.


While it is pleasing to see the continual upsurge in scientific articles describing research on drugs for cancer therapy, this increase in the literature makes it everharder to keep up, even with selected topics in the field. Thus it is very good to see this e-Book venture by Bentham Science Publishers, containing selected, author-updated papers originally published in Anti-Cancer Agents in Medicinal Chemistry during 2008-2010. A particular virtue of this approach is that it obtains additional value from all the effort that is initially put into writing a review, by keeping it up-to-date and thus more useful. The present Volume 1 contains reviews of many of the classes of drugs of contemporary interest for cancer therapy, and offers a new way of keeping up with a field of interest, or being rapidly introduced to a new field. I congratulate Michelle Prudhomme, Editor-in- Chief of Anti-Cancer Agents in Medicinal Chemistry, for this interesting new venture, which I commend to you.

William A. Denny
Auckland Cancer Society Research Centre
University of Auckland
New Zealand